PA
ONC

Perceptive Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Perceptive Advisors’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-200,000
Closed -$4K – 128
2019
Q4 		$4K Sell
200,000
-200,000
-50% -$33.2M ﹤0.01% 114
2019
Q3 		$2.7M Buy
+400,000
New +$53.1M 0.07% 80

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Perceptive Advisors's ONC Position: Q4 2018 in Review

Perceptive Advisors sold out of BeOne Medicines Ltd (ONC) in Q4 2018, closing a stake of 5,700 shares — an estimated $982K sold.

Perceptive Advisors first reported a position in ONC in Q3 2016 and held it in 6 quarters. The position peaked at $4.07M in Q3 2016. 192 funds tracked by Wall St. Rank hold ONC as of Q4 2018.

  • Perceptive Advisors reported no remaining BeOne Medicines Ltd position as of Q4 2018 after selling out during the quarter.
  • Perceptive Advisors sold 5,700 BeOne Medicines Ltd shares in Q4 2018, an estimated $982K.
  • Perceptive Advisors first reported a position in BeOne Medicines Ltd in Q3 2016 and held it in 6 quarters.
  • Perceptive Advisors's BeOne Medicines Ltd position peaked at $4.07M in Q3 2016.
  • 192 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2018.

Based on Perceptive Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.